Front Page News
Cure SMA Funding Leads to 16 New Research Publications in 2018
An important goal of our research funding strategy is to share scientific findings with the broader scientific community. Scientists who receive Cure SMA funding often […]
Read More ›Community Spotlight: The Berkovits Family
When Milo Berkovits was seven months old, his daycare teacher noticed he was not reaching his milestones. What followed from there on were visits to […]
Read More ›Advocacy Year-in-Review 2018
For Cure SMA, 2018 has been a year of great progress. As we continue to make strides into 2019, it is important to take a […]
Read More ›Biogen Issues Q4 Community Statement on Spinraza
Bigoen has provided the below community statement on Spinraza. Dear Members of the SMA community, As we approach the two-year anniversary of the U.S. Food […]
Read More ›AveXis Issues Community Statement on BLA Acceptance
AveXis has provided the following community statement on the BLA submission and acceptance for their investigational therapy, AVXS-101 – now known as ZOLGENSMA®. Dear SMA […]
Read More ›Closing out 2018 with Good News: Virginia Adopts SMA to their Newborn Screening Panel, Arizona Moves Closer to Adopting SMA Newborn Screening and Illinois Medicaid Covers Spinraza Treatment
The SMA community has multiple victories to celebrate as the year comes to an end. Thank you to all our amazing families and advocates who […]
Read More ›Fall 2018 Issue of Compass Now Available
The fall 2018 issue of Compass is now available online. This issue of Compass covers the SMA Care Center Network and its goal of developing an […]
Read More ›Novartis Announces FDA Filing Acceptance and Priority Review for AVXS-101
Novartis today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for AVXS-101, now known as ZOLGENSMA® […]
Read More ›Register for Cure SMA’s Webinar on SMA Treatments and Clinical Trials
On Wednesday, December 12th, at 12:00pm CST (10:00am PST/11:00am MST/1:00pm EST) Cure SMA will hold a webinar updating the community on the latest information on […]
Read More ›Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of SMA
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the […]
Read More ›